Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Agrippal

- PMLiVE

Novartis gets OK for panobinostat in myeloma

First HDAC to receive positive FDA review

- PMLiVE

Novartis’ heart failure drug could get FDA nod in summer

Some predicting sales of $5bn within four years for LCZ696

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

Novartis building

Novartis’ Japanese subsidiary threatened with suspension

Company failed to report more than 3,200 adverse events among patients taking its drugs

- PMLiVE

Global pledge to immunise 300 million children

Commitment made at GAVI Pledging Conference follows criticism of high vaccine prices

Novartis building

Novartis sees first benefits from efficiency drive

Made $1.6bn in savings in 2014

- PMLiVE

Novartis begins sale talks for Horsham, UK site

Enters negotiations with the University of Brighton

- PMLiVE

Novartis launches another localised NHS eye service in UK

Will provide specialised care to people of Coventry

- PMLiVE

Indian generics firm GVK set to be hit with European sales ban

EU regulator raises concerns on conduct of drug studies in India

- PMLiVE

Call for GSK and Pfizer to reduce vaccine price

MSF campaigns to lower cost of pneumococcal shot to $5 per child in developing countries

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

China flag thumb

China approves home-grown polio vaccine

Country clamps down on recent outbreaks of disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links